United Therapeutics (UTHR) CEO trusts exercise options, sell 9,500 shares
Rhea-AI Filing Summary
United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt, through family trusts where she shares investment power, exercised 9,500 stock options at a strike price of $135.42 to acquire the same number of common shares, then sold 9,500 shares in several open-market or private transactions at weighted average prices in the low $520s per share. The option exercise and related sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which will continue until the earlier of exercising 1,734,410 stock options expiring March 15, 2027 or December 31, 2026.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 9,500 shares ($3.70M approx. pre-tax spread)
Exercise and Sale
13 txns
Insider
ROTHBLATT MARTINE A
Role
Chairperson & CEO
Sold
9,500 shs ($4.99M)
Approx. gross sale proceeds
$4.99M
Approx. exercise cost
$1.29M
Approx. pre-tax spread
$3.70M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option F1, F11 | 9,500 | $0.00 | $0.00 |
| Exercise | Common Stock F1, F2 | 9,500 | $135.42 | $1.29M |
| Sale | Common Stock F1, F3, F2 | 644 | $523.0381 | $337K |
| Sale | Common Stock F1, F4, F2 | 1,486 | $523.8749 | $778K |
| Sale | Common Stock F1, F5, F2 | 4,846 | $524.8842 | $2.54M |
| Sale | Common Stock F1, F6, F2 | 2,084 | $525.798 | $1.10M |
| Sale | Common Stock F1, F7, F2 | 400 | $526.923 | $211K |
| Sale | Common Stock F1, F2 | 40 | $528.96 | $21K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock F8 | -- | -- | -- |
| holding | Common Stock F9 | -- | -- | -- |
| holding | Common Stock F10 | -- | -- | -- |
Holdings After Transaction:
Stock Option — 236,910 shares (Indirect, by Trust);
Common Stock — 628,049 shares (Indirect, by Trust);
Common Stock — 40,513 shares (Direct);
Common Stock — 166 shares (Indirect, by Spouse)
Footnotes (11)
- F1. This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026.
- F10. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F11. Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries.
- F2. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F3. This transaction was executed in multiple trades at prices ranging from $522.43 to $523.38. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4. This transaction was executed in multiple trades at prices ranging from $523.43 to $524.41. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5. This transaction was executed in multiple trades at prices ranging from $524.43 to $525.41. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6. This transaction was executed in multiple trades at prices ranging from $525.43 to $526.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7. This transaction was executed in multiple trades at prices ranging from $526.50 to $527.45. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F8. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F9. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
Key Figures
Stock options exercised: 9,500 shares
Common shares sold: 9,500 shares
Option exercise price: $135.42 per share
+4 more
7 metrics
Stock options exercised
9,500 shares
Stock options exercised on 2026-07-30 at $135.42 strike price
Common shares sold
9,500 shares
Aggregate common shares sold in open market or private transactions on 2026-07-30
Option exercise price
$135.42 per share
Conversion or exercise price of stock options expiring March 15, 2027
Trading plan option pool
1,734,410 stock options
Maximum options subject to the Rule 10b5-1 plan, all expiring March 15, 2027
Direct common share holdings
40,513 shares
Common stock held directly by the reporting person after 2026-07-30
Spouse indirect holdings
166 shares
Common stock held indirectly by spouse after 2026-07-30
Representative sale price
$523.0381 per share
Weighted average price for a 644-share sale on 2026-07-30
Key Terms
Rule 10b5-1 trading plan, stock options, weighted average price, family trusts
4 terms
Rule 10b5-1 trading plan financial
"This exercise of stock options and sale ... was pursuant to a pre-arranged 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
stock options financial
"This exercise of stock options and sale of the resulting shares of common stock"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
weighted average price financial
"The price reported above reflects the weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
family trusts financial
"Shares held in family trusts as to which the Reporting Person shares investment power"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transactions did United Therapeutics (UTHR) disclose for Martine Rothblatt on July 30, 2026?
Family trusts associated with CEO Martine A. Rothblatt exercised 9,500 United Therapeutics options at a $135.42 strike and sold 9,500 common shares. The trades occurred in several open-market or private transactions at weighted average prices around the low $520s per share.
What are the key terms of the Rule 10b5-1 trading plan referenced for UTHR?
The trades occurred under a pre-arranged Rule 10b5-1 plan adopted November 7, 2025. The plan will continue until the earlier of exercising 1,734,410 stock options, all expiring March 15, 2027, or December 31, 2026, providing structured timing for option exercises and sales.